The association between statin use and endometrial cancer survival outcome

Li, Jia; Liu, Ruijuan; Sun, Zengqi; Tang, Shifeng; Wang, Lu; Liu, Cun; Wei, Zhao; Yao, Yan; Sun, Changgang

doi:10.1097/md.0000000000013264

Cited by 12 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In association with progestin therapy (local or systemic), different drugs have been investigated such as GnRH agonists, aromatase inhibitors [79], aspirin [80,81], and statins [82]. GnRH agonists combined with IUS have demonstrated satisfactory results in terms of complete response and recurrence rate.…”

Section: Other Drugsmentioning

confidence: 99%

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women

et al. 2022

View full text Add to dashboard Cite

Total hysterectomy and bilateral adnexectomy is the standard treatment for atypical endometrial hyperplasia and early-stage endometrial cancer. However, the recommended surgical treatment precludes future pregnancy when these conditions are diagnosed in women in their fertile age. In these patients, fertility-sparing treatment may be feasible if the desire for childbearing is consistent and specific conditions are present. This review summarizes the available evidence on fertility-sparing management for atypical endometrial hyperplasia and early-stage endometrial cancer. Historically, oral progestins have been the mainstay of conservative management for atypical endometrial hyperplasia and stage IA endometrioid endometrial cancer with no myometrial invasion, although there is no consensus on dosage and treatment length. Intrauterine progestin therapy has proved a valid alternative option when oral progestins are not tolerated. GnRH analogs, metformin, and hysteroscopic resection in combination with progestins appear to increase the overall efficacy of the treatment. After a complete response, conception is recommended; alternatively, maintenance therapy with strict follow-up has been proposed to decrease recurrence. The risk of disease progression is not negligible, and clinicians should not overlook the risk of hereditary forms of the disease in young patients, in particular, Lynch syndrome. Hysterectomy is performed once the desire for childbearing desire has been established. The conservative management of atypical endometrial hyperplasia and early-stage endometrial cancer is feasible, provided a strong desire for childbearing and permitting clinical–pathological conditions. However, patients must be aware of the need for a strict follow-up and the risk of progression with a possible consequent worsening of the prognosis. More homogenous and well-designed studies are necessary to standardize and identify the best treatment and follow-up protocols.

show abstract

Section: Other Drugsmentioning

confidence: 99%

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Likewise, research indicates a reduction in morbidity, as well as a more favorable clinical course as a result of the application of drugs, such as metformin, which reduce these factors [58][59][60]. However, the results of the studies on the use of statins in EC remain inconclusive [61][62][63][64][65], and the observational studies often compare the effects of two drugs, i.e., antidiabetic metformin and a selected compound from the statins class [48,49].…”

Section: Endometrial Cancermentioning

confidence: 99%

“…Slightly different results have been presented by Li and co-workers [63]. Using electronic databases, they analysed the data of 5923 EC women from Austria, Denmark, Israel, UK and USA.…”

Section: Endometrial Cancermentioning

confidence: 99%

Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women

et al. 2020

View full text Add to dashboard Cite

Statins, also known as HMG-CoA inhibitors, are a class of bioactive small molecules that efficiently reduce the levels of cholesterol, and therefore are commonly used to manage and prevent various cardiovascular diseases. With respect to their original medical indications, statins are currently in the group of the most prescribed drugs worldwide. Of note is that statins are perceived actually rather as agents that have pleiotropic activities; in addition to their inhibitory activity on the production of endogenous cholesterol. Statins may also affect cell proliferation, angiogenesis and/or migration (metastasis) of different cancer cells, and play a positive role in the chemoprevention of cancer, thus being the excellent candidates to be repurposed in oncology. Particularly intriguing in this context seems to be the promising role of statins on both the incidence and course of common malignant neoplasms in women. In this article, we review and discuss the effect of the use of statins in the treatment of three types of cancer, i.e., breast, endometrial and ovarian cancer, with the highest mortality among gynecological cancers.

show abstract

“…For cancers of the female reproductive organs, previous meta‐analyses have found mixed results regarding the protective effect of statins against breast cancer incidence and survival 15,19‐23 . In addition, two meta‐analyses found mixed results concerning the protective effects of statins against cervix uteri cancer 24,25 . Several meta‐analyses of epidemiological studies have also found a reduced risk of ovarian cancer incidence and mortality among statin users 26‐34 .…”

Section: Introductionmentioning

confidence: 99%

Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database

Kim

Ahn

Kim

2021

Intl Journal of Cancer

View full text Add to dashboard Cite

Previous studies have reported inconsistent findings concerning the impact of statin use on cancer prevention. Our study examined the association between statin use and cancer incidence and mortality related to breast and gynecologic cancers in South Korea. A population‐based cohort study was conducted using the National Health Insurance claims database. Women aged 45 to 70 years old who had taken statins for at least 6 months were compared to statin non‐users of the same age from January 2005 to June 2013. The primary outcomes were cancer incidence and mortality related to breast cancer, total gynecologic cancers, cervix uteri cancer and ovarian cancer. Cox proportional hazards regression was conducted to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs). Out of 587 705 women, there were 3591 cases of breast cancer, 2239 cases of gynecologic cancers and 565 breast and total gynecologic cancer deaths during 7.6 person‐years. The aHRs for the association between the risk of each cancer and statin use were 0.88 (95% CI 0.79‐0.97) for breast cancer and 0.83 (95% CI 0.67‐0.99) for cervix uteri cancer. Statin use was associated with decreased breast cancer mortality (HR = 0.65, 95% CI 0.43‐0.99) and total gynecologic cancer mortality (HR = 0.70, 95% CI 0.50‐0.98). A dose‐response relationship was only found for all‐cancer mortality. Statin use for at least 6 months was significantly associated with a lower risk of breast and cervix uteri cancer incidence, and with lower mortality of breast and gynecologic cancers. Further research on these associations will be needed.

show abstract

The association between statin use and endometrial cancer survival outcome

Cited by 12 publications

References 49 publications

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women

Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women

Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database

Contact Info

Product

Resources

About